Data: 09/08/2026
Total encontrado: 9
1/9US=94 / Biol/Mol
Matthews DJ, Gerritsen ME. Tyrosine kinase inhibitors. In: ___. Targeting protein kinases for cancer therapy. New Jersey: Wiley, 2010. p. 435-525. ISBN 978-0-470-22965-1.

INIBIDORES DA TIROSINA QUINASE; INIBIDOR BCR-ABL; INIBIDORES SRC; INIBIDORES JAK2; INIBIDORES EGFR; INIBIDORES IGF1R; INIBIDORES FLT3; INIBIDORES KIT; INIBIDORES MET/RON; INIBIDORES RET; INIBIDORES FAK; INIBIDOR TGFB

2/9US=84 / Biol/Mol
Souchelnytskyi S. TGF-B superfamily members in normal and tumor biology: proteomics analysis of TGFB superfamily members. In: Jakowlew SB. Transforming growth Factor-beta in cancer therapy: basic and clinical biology. Amsterdam: Elsevier, 2008. p. 319-31. (Cancer Drug Discovery and Development) ISBN 978-1-58829-714-3.

PROTEOMICA; SINALIZACAO; FACTOR DE CRESCIMENTO TRANSFORMANTE-B; PROTEINAS MORFOGENETICAS DO OSSO; SMAD

3/9US=84-A / Biol/Mol
Barrios-Rodiles M, Viloria-Petit A, Brown KR, Jurisica I, Wrana JL. Transformig growth factor-B in developing and advanced cancers: high-throughput screening of protein interaction networks in the TGFB interactome: understanding the signaling mechanisms driving tumor progression. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 265-84. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

RENDIMENTO ELEVADO; INTERACOES PROTEINA-PROTEINA; REDES; EMT; METASTASE

4/9US=84-A / Biol/Mol
Wilkinson DS, Barton MC. Transformig growth factor-B in developing and advanced cancers: tumor suppressors p53 and TGFB converge to regulate the alpha-fetoprotein oncodevelopmental tumor marker. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 309-20. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

P53; SMAD2; SMAD4; SNON; P73; CROMATINA; FIGADO; HEPATOMA

5/9US=84-A / Biol/Mol
Wilkinson DS, Barton MC. Transformig growth factor-B in developing and advanced cancers: tumor suppressors p53 and TGFB converge to regulate the alpha-fetoprotein oncodevelopmental tumor marker. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 309-20. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

P53; SMAD2; SMAD4; SNON; P73; CROMATINA; HEPATOMA

6/9US=84-A / Biol/Mol
Andarawewa KL, Kirshner J, Mott JD, Barcellos-Hoff MH. Transformig growth factor-B in developing and advanced cancers: TGFB: roles in DNA damage responses. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 321-33. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

TGFB; DNA DANO; RADIACAO IONIZANTE

7/9US=84-A / Biol/Mol
Micke P, Moustakas A, Ohshima M, Kappert K. Transformig growth factor-B in developing and advanced cancers: cancer-associated fibroblasts and the role of TGF-B. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 417-41. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

ASSOCIADAS CANCER FIBROBLASTOS; ESTROMA; ASSOCIADAS CANCER FIBROBLASTOS; TUMOR DO ESTROMA INTERACCAO; MIOFIBROBLASTOS; TERAPIA-ALVO; TGFB-1; MICROARRAY; EXPRESSAO DO GENE; CANCER

8/9US=468 / Tese/FAP
Batista RMSS. Avaliação da expressão imunoistoquímica de proteínas da via de sinalização mediada por TGF Beta como preditores de resposta à quimioterapia pré-operatória em adultos portadores de sarcoma de partes moles de alto grau em extremidades. [Protein expression evaluation of protein of genes belonging to the TGF&*946; pathway as predictors of response to preoperative chemotherapy with doxorubicin and ifosfamide in adult patients with high grade soft tissue sarcomas located in extremities]. São Paulo, 2013. 111 p. Tese(Doutorado)-Fundação Antonio Prudente.

Disponível em: http://accamargo.phlnet.com.br/Doutorado/2013/RanyelSpencer/RanyelSpencer.pdf

Curriculum Lattes

QUIMIOTERAPIA; SARCOMA. CIRURGIA; FATOR DE CRESCIMENTO TRANSFORMADOR BETA; EXTREMIDADES

9/9US=928 / Tese/FAP
Saito AO. Correlação entre os desfechos do tratamento com nivolumabe e a resposta imune e infamatória em pacientes portadores de melanoma e câncer de pulmão. [Correlation between nivolumab treatment outcomes and immune and inflammatory response in melanoma and lung cancer patients]. São Paulo, 2021. 92 p. Dissertação(Mestrado)-Fundação Antonio Prudente.

Disponível em: https://accamargo.phlnet.com.br/MESTRADO/2021/AOSaito/AOSaito.pdf

CANCER DE PULMAO; MELANOMA; NEOPLASIAS PULMONARES; CANCER DE PULMAO DE CELULAS NAO PEQUENAS; CARCINOMA PULMONAR DE CELULAS NAO PEQUENAS; NIVOLUMABE